AR113221A1 - Agentes antifúngicos utilizados en combinación - Google Patents

Agentes antifúngicos utilizados en combinación

Info

Publication number
AR113221A1
AR113221A1 ARP180100881A ARP180100881A AR113221A1 AR 113221 A1 AR113221 A1 AR 113221A1 AR P180100881 A ARP180100881 A AR P180100881A AR P180100881 A ARP180100881 A AR P180100881A AR 113221 A1 AR113221 A1 AR 113221A1
Authority
AR
Argentina
Prior art keywords
combination
antifungal agents
filamentous fungi
antifungal
enfumafungin
Prior art date
Application number
ARP180100881A
Other languages
English (en)
Inventor
Gonzalez David A Angulo
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of AR113221A1 publication Critical patent/AR113221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Uso de compuestos antifúngicos triterpenoides derivados de enfumafungina, en combinación con otros agentes antifúngicos como por ejemplo, azoles, polienos, lipopéptidos y alilamidas para tratar enfermedades fúngicas. Más particularmente, combinaciones antifúngicas triterpenoides derivadas de enfumafungina (o sus sales farmacéuticamente aceptables) que son inhibidores de la síntesis de (1,3)-b-D-glucano, en combinación con otros agentes antifúngicos como por ejemplo, agentes activos en hongos filamentosos, que actúan contra hongos filamentosos, dichas combinaciones incluyen de manera enunciativa pero no limitativa, voriconazol, isavuconazol, posaconazol, itraconazol, y anfotericina B, para el tratamiento y/o prevención de infecciones producidas por hongos filamentosos.
ARP180100881A 2017-04-10 2018-04-09 Agentes antifúngicos utilizados en combinación AR113221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762483647P 2017-04-10 2017-04-10

Publications (1)

Publication Number Publication Date
AR113221A1 true AR113221A1 (es) 2020-02-19

Family

ID=62063223

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100881A AR113221A1 (es) 2017-04-10 2018-04-09 Agentes antifúngicos utilizados en combinación

Country Status (13)

Country Link
US (2) US11110102B2 (es)
EP (1) EP3609539A1 (es)
JP (2) JP7263313B2 (es)
KR (2) KR20240110109A (es)
CN (1) CN110769854B (es)
AR (1) AR113221A1 (es)
AU (1) AU2018253031B2 (es)
CA (1) CA3059225A1 (es)
EA (1) EA201992413A1 (es)
MA (1) MA49889A (es)
MX (1) MX2019012116A (es)
TW (1) TWI806861B (es)
WO (1) WO2018191077A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4732902A2 (en) * 2017-08-04 2026-04-29 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph
MA55081A (fr) * 2019-02-27 2022-01-05 Scynexis Inc <smallcaps/>? ? ?pneumocystis? ? ? ? ?antifongiques triterpénoïdes pour le traitement ou la prévention de la pneumonie àspp
BR112021022876A2 (pt) * 2019-05-16 2022-04-12 Scynexis Inc Método para descolonizar candida auris de uma área anatômica de um sujeito

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
DK2007396T3 (da) 2006-04-03 2013-03-18 Merck Sharp & Dohme Enfumafungin-derivat som antimykotika
RS53731B1 (sr) * 2008-08-12 2015-06-30 Scynexis, Inc. Antigljivični agensi
US8188085B2 (en) 2008-08-12 2012-05-29 Merck Sharp & Dohme Corp. Antifungal agents
DK3221308T3 (en) 2014-11-21 2018-12-10 F2G Ltd Antifungals
LT3247711T (lt) 2015-01-19 2022-05-25 Scynexis, Inc. Naujos scy-078 druskos ir polimorfai

Also Published As

Publication number Publication date
KR102683355B1 (ko) 2024-07-10
WO2018191077A1 (en) 2018-10-18
CA3059225A1 (en) 2018-10-18
TWI806861B (zh) 2023-07-01
JP2020513037A (ja) 2020-04-30
JP7574268B2 (ja) 2024-10-28
EP3609539A1 (en) 2020-02-19
EA201992413A1 (ru) 2020-03-16
JP2023030113A (ja) 2023-03-07
US20180325919A1 (en) 2018-11-15
MA49889A (fr) 2020-06-24
US20220202833A1 (en) 2022-06-30
KR20240110109A (ko) 2024-07-12
AU2018253031B2 (en) 2024-04-11
CN110769854B (zh) 2023-01-13
MX2019012116A (es) 2019-11-21
AU2018253031A1 (en) 2019-10-31
US11110102B2 (en) 2021-09-07
BR112019021138A2 (pt) 2020-05-12
JP7263313B2 (ja) 2023-04-24
KR20190133251A (ko) 2019-12-02
CN110769854A (zh) 2020-02-07
TW201842915A (zh) 2018-12-16

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CO2017009023A2 (es) Combinaciones de compuestos activos desde el punto de vista fungicida
MX2013012123A (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y un compuesto fungicida.
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
CO2018012894A2 (es) Derivados de pirazol como inhibidores de calicreína plasmática
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CO2017005991A2 (es) Una combinación fungicida que comprende una carboxamida de indanilo difluorometil-nicotínico y un inhibidor de la biosíntesis de ergosterol
MX2018009861A (es) Compuesto novedoso de tiofeno 2,3,5-sustituido como inhibidor de la proteina cinasa.
CO2017005990A2 (es) Combinaciones de compuestos activos que comprenden (a) una carboxamida de indanilo difluorometil-nicotínico de fórmula (i) y otro compuesto activo como fungicida (b)
CO2017006983A2 (es) Una composición fungicida que comprende una n-ciclopropil- n-[bencilo sustituido]-3-(difluorometil)-5-fluoro-1- metil-1-h-pirazol-4-carboxamida o derivado de tiocarboxamida y dos compuestos fungicidas activos adicionales
MX2018003930A (es) Inhibidores de calicreína plasmática humana.
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CO2017005993A2 (es) Combinaciones de compuestos activos
UY37306A (es) Combinaciones de compuestos activos
AR113221A1 (es) Agentes antifúngicos utilizados en combinación
MX2019002149A (es) Metodo para el tratamiento de prurito y/o comezon.
MX388377B (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
CL2017002229A1 (es) Inhibidores de bace1.
NZ735783A (en) Antifungal 4-(4-(4-(((3r,5r)-5-((1 h -1,2,4-triazol-1 -yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methoxy)- 3-methylphenyl)piperazin-1 -yl )-n -(2-h yd roxycyc lo h exyl) b e nzam i d e, or a pharmaceutically acceptable salt thereof.
UY37397A (es) Combinaciones de compuestos activos
AR103381A1 (es) Composición farmacéutica para el tratamiento de micosis
MX2019003697A (es) Sal de metformina de elafibranor que muestra una actividad doble para el tratamiento de la obesidad asociada a la esteatohepatitis no alcoholica (nash) y a la hipertrigliceridemia.
MX2016009567A (es) Composicion antifungica.
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.

Legal Events

Date Code Title Description
FC Refusal